A new scoring system: PAT2C2H score. Its clinical use and comparison with HATCH and CHA2DS2-VASc scores in predicting arrhythmia recurrence after cryoballoon ablation of paroxysmal atrial fibrillation

被引:5
|
作者
Cay, Serkan [1 ]
Kara, Meryem [1 ]
Ozcan, Firat [1 ]
Ozeke, Ozcan [1 ]
Korkmaz, Ahmet [1 ]
Cetin, Hande [1 ]
Aksu, Tolga [2 ,3 ]
Topaloglu, Serkan [1 ]
机构
[1] Univ Hlth Sci, Div Arrhythmia & Electrophysiol, Dept Cardiol, Ankara City Hosp, Yuksek Ihtisas Cardiovasc Bldg, Ankara, Turkey
[2] Yeditepe Univ Hosp, Dept Elect, Istanbul, Turkey
[3] Yeditepe Univ Hosp, Dept Cardiol, TR-41500 Istanbul, Turkey
关键词
Atrial fibrillation; Cryoballoon; Recurrence; Scoring systems; PULMONARY VEIN ISOLATION; CATHETER ABLATION; OUTCOMES; CHADS(2); POPULATION; C2HEST; IMPACT;
D O I
10.1007/s10840-022-01328-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Several clinical risk factors and scoring systems have been proposed to predict arrhythmia recurrence after atrial fibrillation (AF) ablation. We sought to determine the ability of a new score to predict atrial arrhythmia recurrence after cryoballoon (CB) ablation of AF and whether the new score shows superior efficiency compared to previously offered scores. Methods A total of 419 patients with paroxysmal AF who underwent their first CB ablation were included. Baseline clinical variables were analyzed, and independent predictors of recurrence at 12 months were used to develop the PAT(2)C(2)H score. The predictive capability of the new score was calculated and compared with the currently available risk scores. Results Chronic obstructive pulmonary disease, left atrial dilatation, transient ischemic attack or stroke, congestive heart failure, and hypertension were independent predictors of recurrence. The PAT(2)C(2)H score which was developed from these variables had a better clinical predictive capability of arrhythmia recurrence compared to HATCH and CHA(2)DS(2)-VASc scores. With increasing PAT(2)C(2)H score and score severity (low, score of 0; moderate, score of 1-2; and high, score of >= 3), the proportion of patients with recurrence was increased from 7% (score = 0, severity = low) to 59% (score >= 3, severity = high). Conclusions The PAT(2)C(2)H score may help to identify patients who are likely benefited most from CB ablation of paroxysmal AF and who should be monitored more closely for arrhythmia recurrence at 12 months.
引用
收藏
页码:701 / 710
页数:10
相关论文
共 50 条
  • [41] The ABC-stroke risk score was superior to the CHA2DS2-VASc score for predicting stroke in atrial fibrillation Commentary
    Hankey, Graeme J.
    ANNALS OF INTERNAL MEDICINE, 2016, 164 (12) : JC69 - JC69
  • [42] Use of Antithrombotic Therapy According to CHA2DS2-VASc Score in Patients With Atrial Fibrillation in Primary Care
    Barrios, Vivencio
    Escobar, Carlos
    Calderon, Alberto
    Rodriguez Roca, Gustavo C.
    Luis Llisterri, Jose
    Polo Garcia, Jose
    REVISTA ESPANOLA DE CARDIOLOGIA, 2014, 67 (02): : 150 - 151
  • [43] CHA2DS2-VASc score predicted extensive substrate and poor outcome of catheter ablation of persistent atrial fibrillation
    Tang, R. -B.
    Dong, J. -Z.
    Liu, X. -H.
    Yu, R. -H.
    Long, D. -Y.
    Sang, C. -H.
    Ning, M.
    Jiang, C. -X.
    Bai, R. O. N. G.
    Ma, C. -S.
    EUROPEAN HEART JOURNAL, 2015, 36 : 901 - 901
  • [44] CHA2DS2-VASc score and blood biomarkers to identify patients with atrial high-rate episodes and paroxysmal atrial fibrillation
    Wakula, Paulina
    Neumann, Benjamin
    Kienemund, Jens
    Thon-Gutschi, Eva
    Stojakovic, Tatjana
    Manninger, Martin
    Scherr, Daniel
    Scharnagl, Hubert
    Kapl, Martin
    Pieske, Burkert
    Heinzel, Frank R.
    EUROPACE, 2017, 19 (04): : 544 - 551
  • [45] Risk scoring by CHADS2 and CHA2DS2-VASc as predictors for long-term outcomes after surgical ablation for atrial fibrillation
    Lauritzen, D.
    Vodstrup, H. J.
    Christensen, T. D.
    Onat, M.
    Christensen, R.
    Heiberg, J.
    EUROPEAN HEART JOURNAL, 2020, 41 : 620 - 620
  • [46] Comparison of CHADS2 and CHA2DS2-VASC anticoagulation recommendations: evaluation in a cohort of atrial fibrillation ablation patients
    Winkle, Roger A.
    Mead, R. Hardwin
    Engel, Gregory
    Kong, Melissa H.
    Patrawala, Rob A.
    EUROPACE, 2014, 16 (02): : 195 - 201
  • [47] Usefulness for CHA2DS2-VASc score for predicting adverse events in high risk anticoagulated patients with atrial fibrillation
    Roldan, V.
    Marin, F.
    Gallego, P.
    Muina, B.
    Torregrosa, J. M.
    Galvez, J.
    Hernandez-Romero, D.
    Valdes, M.
    Vicente, V.
    Lip, G. Y. H.
    EUROPEAN HEART JOURNAL, 2011, 32 : 464 - 464
  • [48] Comparison of emerging blood biomarkers, NTproBNP and the CHA2DS2-VASc score in the prediction of paroxysmal atrial fibrillation in patients with continuous rhythm monitoring
    Wakula, P.
    Neumann, B.
    Kienemund, J.
    Thon-Gutschi, E.
    Stojakovic, T.
    Scharnagl, H.
    Pieske, B.
    Kapl, M.
    Heinzel, F. R.
    EUROPEAN HEART JOURNAL, 2015, 36 : 913 - 913
  • [49] Comparison of CHA2DS2-VASc and C2HEST scores for predicting the incidence of atrial fibrillation among patients with end-stage renal disease
    Hu, Wei-Syun
    Lin, Cheng-Li
    PERFUSION-UK, 2020, 35 (08): : 842 - 846
  • [50] Performance of the CHA2DS2-VASc score in predicting new onset atrial fibrillation during hospitalization for community-acquired pneumonia
    Pieralli, Filippo
    Biondo, Beatrice
    Vannucchi, Vieri
    Falcone, Marco
    Antonielli, Elisa
    De Marzi, Giulia
    Casati, Carlotta
    Maddaluni, Lucia
    Nozzoli, Carlo
    Olivotto, Iacopo
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2019, 62 : 24 - 28